Oncology — a weekly podcast briefing of the most significant peer-reviewed oncology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.
Editor's Pick: Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer (New England Journal of Medicine, 2026)
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning new targeted and immune strategies in lung cancer, immunotherapy for mismatch repair-deficient colorectal cancer, and antibody-drug conjugates moving into earlier l…
This week's papers:
1. Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. — New England Journal of Medicine 2026
2. Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC. — New England Journal of Medicine 2026
3. Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy. — New England Journal of Medicine 2026
4. Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-… — The Lancet 2026
5. Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial. — Annals of Oncology 2026
6. Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal… — Annals of Oncology 2026
7. 14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, rand… — The Lancet 2026
8. Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC. — New England Journal of Medicine 2026
9. Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial. — JAMA 2026
10. Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer. — New England Journal of Medicine 2026
Listen at https://audioscholar.cc/episode/esntzj8j3z
21 Oct 2026
This Week in Oncology — Oct 21, 2026
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning chemotherapy-free and trans…
This week's papers:
1. Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL. — New England Journal of Medicine 2026
2. First-In-Human Study of 211At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic Maligna… — Journal of Clinical Oncology 2026
3. Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IM… — Journal of Clinical Oncology 2026
4. Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 ra… — Annals of Oncology 2026
5. DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast Cancer. — Clinical Cancer Research 2026
6. Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations. — Cancer Cell 2026
7. Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study. — Journal of Clinical Oncology 2026
8. Treatment of Advanced Biliary Tract Cancer: ASCO Living Guideline, Version 2026.1.0. — Journal of Clinical Oncology 2026
9. Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial. — Nature Medicine 2026
10. Nivolumab-Ipilimumab for Localized Microsatellite Instability-High Gastric/Gastroesophageal Junction Adenocarcinoma: The Phase 2 NEONIPIGA Nonrandomized Clinic… — JAMA Oncology 2026
Listen at https://audioscholar.cc/episode/qycvs4rbnr
14 Oct 2026
This Week in Oncology — Oct 14, 2026
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning breast cancer radiation, ab…
This week's papers:
1. Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505). — Journal of Clinical Oncology 2026
2. NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. — Journal of Clinical Oncology 2026
3. Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month f… — The Lancet Oncology 2026
4. Universal Germline Genetic Testing after a Diagnosis of Cancer. — Cancer Discovery 2026
5. Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, singl… — The Lancet Oncology 2026
6. Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study. — Annals of Oncology 2026
7. Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial. — JAMA Oncology 2026
8. Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer. — Journal of Clinical Oncology 2026
9. VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy. — Journal of Clinical Oncology 2026
10. RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial. — Journal of Clinical Oncology 2026
Listen at https://audioscholar.cc/episode/swnfuv2tsd
Contact AudioScholar Oncology Weekly
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of AudioScholar Oncology Weekly?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
